Back to top
more

Viridian Therapeutics (VRDN)

(Delayed Data from NSDQ)

$16.86 USD

16.86
505,122

-0.55 (-3.16%)

Updated Aug 4, 2025 03:59 PM ET

After-Market: $16.87 +0.01 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 1.15% and 131.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Legend Biotech Corporation Sponsored ADR (LEGN) Stock Jumps 14.2%: Will It Continue to Soar?

by Zacks Equity Research

Legend Biotech Corporation Sponsored ADR (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -23.26% and 63.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Trevena (TRVN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Trevena (TRVN) delivered earnings and revenue surprises of 18.18% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 50% and 2.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Berkeley Lights, Inc. (BLI) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Berkeley Lights, Inc. (BLI) delivered earnings and revenue surprises of -26.67% and 14.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Puma Biotech (PBYI) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 950% and 11.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -6.52% and 66.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0% and 3.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 0% and 6.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CorMedix (CRMD) Stock Jumps 14.8%: Will It Continue to Soar?

by Zacks Equity Research

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -18% and 14.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 10.53% and 45.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -5.04% and -79.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Viridian Therapeutics, Inc. (VRDN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Viridian Therapeutics, Inc. (VRDN) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.